atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Globally, BRUKINSA is approved in more than 70 countries
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
